Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies--implications for acquired immunodeficiency syndrome vaccine.
Human immunodeficiency virus type 1 (HIV-1) is phylogenetically classified into groups and clades (or subtypes). Human neutralizing monoclonal antibodies (nMAbs), originally isolated from individuals infected with HIV-1 group M-clade B, neutralized not only primary HIV-1 clade B isolates in vitro but also primary isolates of other group M clades (A, C, D, E, and F). This corrected the previously held notion that primary HIV-1 isolates are resistant to neutralizing antibodies. Here we show that anti-HIV-1 group M-clade B nMAbs potently neutralized primary isolates of the phylogenetically distant HIV-1 group O. We and others have previously shown that passive immunization with human nMAbs protected adult or neonatal primates against infection with simian-human immunodeficiency virus strains encoding HIV-1 group M-clade B envelope genes. The in vitro cross-group neutralization shown here underscores the broad potential of these nMAbs against divergent virus variants and the relevance of their epitopes in the design of acquired immunodeficiency syndrome vaccines.
Ferrantelli
Flavia
F
Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Kitabwalla
Moiz
M
Rasmussen
Robert A
RA
Cao
Chuanhai
C
Chou
Ting-Chao
TC
Katinger
Hermann
H
Stiegler
Gabriela
G
Cavacini
Lisa A
LA
Bai
Yun
Y
Cotropia
Joseph
J
Ugen
Kenneth E
KE
Ruprecht
Ruth M
RM
D016915:AIDS Vaccines; D000911:Antibodies, Monoclonal / Q000276:immunology*; D003429:Cross Reactions; D015195:Drug Design; D014644:Genetic Variation; D015483:HIV Antibodies / Q000276:immunology*; D015497:HIV-1 / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification; D006801:Humans; D009500:Neutralization Tests
D016915:AIDS Vaccines; D000911:Antibodies, Monoclonal; D015483:HIV Antibodies